Capital Structure

in mil. unless spec.
Working Capital

in mil. unless spec.
Growth Rates

in mil. unless spec.
Quarterly Revenue

in mil. unless spec.
Quarterly Earnings Per Share

in mil. unless spec.
Quarterly Dividends Per Share

in mil. unless spec.

Company Description

CEO
Mr. Joseph H. Capper
Full Time Employees
895
Sector
Healthcare
Industry
Biotechnology
Address
1775 West Oak Commons Court, NE Marietta GA United States of America 30062
IPO Date
Feb 12, 2008
Website
mimedx.com
Similar Companies
Business
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.

Company News

  • MiMedx (MDXG) is on the Move, Here's Why the Trend Could be Sustainable

  • Recent Price Trend in MiMedx (MDXG) is Your Friend, Here's Why

  • Recent Price Trend in MiMedx (MDXG) is Your Friend, Here's Why

  • How Much Upside is Left in MiMedx (MDXG)? Wall Street Analysts Think 37.12%

  • MiMedx (MDXG) Is a Great Choice for 'Trend' Investors, Here's Why

  • MIMEDX's Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs

  • Can MiMedx (MDXG) Climb 77.92% to Reach the Level Wall Street Analysts Expect?

  • MiMedx Group, Inc. (MDXG) Q3 2024 Earnings Call Transcript

  • MiMedx (MDXG) Q3 Earnings and Revenues Surpass Estimates

  • MIMEDX Announces Third Quarter 2024 Operating and Financial Results

  • MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30

  • MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue

  • MIMEDX Showcases Leading Allograft Portfolio and Its Latest Scientific and Clinical Evidence at SAWC Fall

  • EX-MiMEDX EMPLOYEES ALLEGE MiMEDX "PRESSURE[D] HEALTHCARE PROVIDERS TO TREAT WOUNDED VETERANS, DIABETICS, CHRONIC WOUND SUFFERERS, AND OTHER PATIENTS WITH MEDICALLY UNNECESSARY OR UNSUITABLE PRODUCTS"

  • THIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES'

  • DEFENDANT FIGHTS BACK AGAINST MiMEDX "BLATANT INTIMIDATION" NON-COMPETE SUIT

  • MiMedx Group, Inc. (MDXG) Q2 2024 Earnings Call Transcript

  • MIMEDX Announces Launch of HELIOGEN™ Fibrillar Collagen Matrix

  • MIMEDX Announces Second Quarter 2024 Operating and Financial Results

  • MIMEDX Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature – Scientific Reports